Esperion Therapeutics (NASDAQ:ESPR) had its price objective hoisted by equities researchers at Northland Securities from $100.00 to $121.00 in a research report issued on Thursday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Northland Securities’ price target points to a potential upside of 64.20% from the company’s previous close.
ESPR has been the topic of a number of other research reports. JPMorgan Chase reissued a “neutral” rating and set a $65.00 price target (up previously from $55.00) on shares of Esperion Therapeutics in a research report on Wednesday, February 21st. ValuEngine upgraded Esperion Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Deutsche Bank upped their price objective on Esperion Therapeutics to $100.00 and gave the stock a “buy” rating in a research note on Friday, March 9th. BidaskClub cut Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, March 9th. Finally, Credit Suisse Group assumed coverage on Esperion Therapeutics in a research note on Wednesday, January 17th. They set an “outperform” rating and a $103.00 price objective for the company. Six equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $96.31.
ESPR opened at $73.69 on Thursday. Esperion Therapeutics has a 12-month low of $30.95 and a 12-month high of $82.68.
In other Esperion Therapeutics news, Director Nicole Vitullo sold 11,674 shares of the stock in a transaction dated Thursday, January 25th. The stock was sold at an average price of $71.79, for a total value of $838,076.46. Following the completion of the sale, the director now directly owns 3,177 shares in the company, valued at $228,076.83. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Roger S. Newton sold 25,000 shares of the stock in a transaction dated Thursday, March 29th. The shares were sold at an average price of $72.37, for a total value of $1,809,250.00. Following the completion of the sale, the director now owns 639,682 shares of the company’s stock, valued at $46,293,786.34. The disclosure for this sale can be found here. Corporate insiders own 32.50% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the business. Raymond James Financial Services Advisors Inc. purchased a new stake in Esperion Therapeutics in the fourth quarter valued at about $222,000. BB&T Securities LLC purchased a new stake in Esperion Therapeutics in the fourth quarter valued at about $263,000. First Mercantile Trust Co. raised its stake in Esperion Therapeutics by 56.0% in the fourth quarter. First Mercantile Trust Co. now owns 4,233 shares of the biopharmaceutical company’s stock valued at $279,000 after buying an additional 1,519 shares during the last quarter. Creative Planning purchased a new stake in Esperion Therapeutics in the fourth quarter valued at about $314,000. Finally, Oakmont Partners LLC purchased a new stake in Esperion Therapeutics in the fourth quarter valued at about $323,000. Institutional investors own 91.66% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Esperion Therapeutics (ESPR) PT Raised to $121.00 at Northland Securities” was reported by Week Herald and is the sole property of of Week Herald. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://weekherald.com/2018/04/21/esperion-therapeutics-espr-pt-raised-to-121-00-at-northland-securities.html.
About Esperion Therapeutics
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.